Our mission is to discover drugs for high unmet medical needs that will improve quality of life for patients with Orphan Diseases.
We stand out by our ability to deliver high value products with relatively little cost in a short period of time. Due to our business model we reduce the risk of drug development.
SOM Biotech has a strong pipeline of products focused on Orphan diseases at preclinical and clinical stages.
NEWS & PRESS RELEASES
SOM Biotech at Veeva R&D Summit Europe 2019
Dr. Raúl Insa, SOM Biotech CEO, participated in the Clinical Roundtable at Veeva R&D Summit […]
SOM Biotech at BIO 2019
SOM Biotech attended the BIO International Convention in Philadelphia last 3-6 June 2019. BIO is […]
SOM Biotech at the International Congress 2019 on Duchenne Muscular Dystrophy and Becker
Dr. Raúl Insa, SOM Biotech CEO, gave a talk on the topic “Repositioning of Utrophin” […]
SOM Biotech collaborates in the organization of the Summer Course about Rare Diseases
SOM Biotech collaborates in the organization of the University of Barcelona’s Summer Course: – “Rare […]
Interview of SOM Biotech for Labiotech.eu
Dr. Raúl Insa, SOM Biotech CEO, gave an interview to Labiotech.eu, leading digital media covering […]
SOM Biotech will attend the 12th Annual Global Discovery to Development Innovation Forum (GDDIF)
Dr. Luca Signorile, Senior computational chemist at SOM Biotech, will be attending the 12th Annual […]
SOM Biotech at TechShare – pre-IPO programme launched by Euronext
Dr. Raúl Insa, SOM Biotech CEO, attended the second campus of the 2018-2019 TechShare programme organized by Euronext and Nova […]
3rd Annual Clinical Trials Summit (CTS) 2019
Dr. Santiago Esteva, Head of Clinical Operations at SOM Biotech, will be presenting at the […]
SOMCT02 Huntington’s disease trial recruits 100% of patient target
On March 8, 2019, the SOMCT02 clinical trial successfully closed recruitment, marking 100% fulfillment of […]
SOM Biotech closes a financing round of 7M Euros
SOM Biotech has just closed a financing round of 7 million euros led by a […]